Bushen Daozhuo Granules for type Ⅲ prostatitis: A multicenter randomized controlled clinical trial.
- Author:
Da-Lin SUN
1
;
Bin CAI
1
;
Bao-Fang JIN
1
;
Guo-Shou XIA
2
;
Zhi-An TANG
2
;
Wen-Tao YANG
2
;
Qiang ZOU
2
;
Guo-Hong SONG
2
;
Jian-Guo LIU
3
;
Hong-le ZHAO
4
;
Ning DAI
4
;
Jia-Hui WANG
4
;
Ya-Long GU
4
;
Ya-Lin ZHAI
4
Author Information
1. Department of Andrology by Integrated Chinese and Western Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, China.
2. Department of Andrology, The Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210001, China.
3. Department of Andrology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an, Shaanxi 710003, China.
4. Department of Andrology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, Anhui 230031, China.
- Publication Type:Journal Article
- Keywords:
Bushen Daozhuo Granules;
type Ⅲ prostatitis;
NIH Chronic Prostatitis Symptom Index
- MeSH:
Capsules;
Chronic Disease;
Delayed-Action Preparations;
Drugs, Chinese Herbal;
adverse effects;
therapeutic use;
Humans;
Male;
Prostatitis;
drug therapy;
pathology;
Sulfonamides;
adverse effects;
therapeutic use;
Tamsulosin;
Treatment Outcome;
Urological Agents;
adverse effects;
therapeutic use
- From:
National Journal of Andrology
2017;23(2):164-168
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the safety and efficacy of Bushen Daozhuo Granules (BDG) in the treatment of type Ⅲ prostatitis.
METHODS:This multicenter randomized controlled clinical trial included 478 patients with type Ⅲ prostatitis, 290 in the trial group and 188 as controls, the former treated with BDG at 200 ml bid and the latter with tamsulosin hydrochloride sustainedrelease capsules at 0.2 mg qd, both for 4 weeks. Before treatment, after 4 weeks of medication, and at 4 weeks after drug withdrawal, we obtained the NIH Chronic Prostatitis Symptom Index (NIHCPSI) scores and compared the safety and effectiveness rate between the two groups of patients.
RESULTS:Compared with the baseline, the NIHCPSI score was markedly decreased in the control group after 4 weeks of medication (21.42 ± 4.02 vs 15.67 ± 3.65, P < 0.05) but showed no statistically significant difference from that at 4 weeks after drug withdrawal (19.03 ± 3.86) (P>0.05), while the NIHCPSI score in the trial group was remarkably lower than the baseline both after 4 weeks of medication and at 4 weeks after drug withdrawal (10.92 ± 2.06 and 12.91 ± 2.64 vs 21.58 ± 3.67, P < 0.05). The trial group exhibited both a higher rate of total effectiveness and safety than the control (P < 0.05).
CONCLUSIONS:BDG is safe and effective for the treatment of type Ⅲ prostatitis.
